

CONTACTS:

Corporate:
Matthew Patterson
Amicus Therapeutics
(609) 662-2000

Media:
Brad Miles
BMC Communications Group
(212) 477 9007

AMICUS THERAPEUTICS FILES FOR INITIAL PUBLIC OFFERING

Cranbury, NJ, May 17, 2006 – Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares in the offering will be sold by Amicus Therapeutics.

Morgan Stanley will act as sole book-runner and lead manager, Goldman, Sachs & Co. will act as joint lead manager, and Pacific Growth Equities, LLC will act as co-manager in the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. When available, a preliminary prospectus may be obtained from Morgan Stanley & Co. Incorporated, by emailing prospectus@morganstanley.com, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014, by telephone at 212-761-6775.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company focused on developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a wide range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to a misfolded protein caused by a genetic mutation. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical need. Amicus' lead compound Amigal™ is in Phase II clinical trials for the treatment of Fabry disease. The company has filed an IND for AT2101 for the treatment of Gaucher disease and intends to initiate Phase I clinical trials in the second half of 2006. The company plans to file an IND for AT2220 for the treatment of Pompe disease in the second half of 2006.

Safe Harbor Statement

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words “may,” “believes,” “will”, “expects,” “anticipates,” or the negation thereof, or similar expressions, which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Amicus to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For those statements, Amicus claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. Amicus will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.